News
Predictive AI is safe and accepted by users in respiratory care
The first of its kind AI study, funded by the NHS to investigate the use of predictive AI in direct care of patients, has encouraging interim primary objective analyses now available, which support that predictive AI is not only safe and effective in healthcare but also well-accepted by users. The news comes on the back of a recent UK- wide survey by The Health Foundation which found both the public and NHS staff support the use of AI in healthcare. Presented at the European Respiratory Society
(ERS) Conference in Vienna, the findings come from the ground-breaking DYNAMIC-AI study, a collaboration between Lenus Health, NHS Greater Glasgow & Clyde and the West of Scotland Innovation Hub to implement and evaluate the use of predictive AI in patients with Chronic Obstructive Pulmonary Disease (COPD). COPD is a serious lung condition affecting 3 million people in the UK and the second most common cause of hospital admissions. A national audit of COPD care in the UK further revealed that nearly half of the COPD patients admitted are readmitted within 90 days, highlighting the necessity for more effective initial treatment and follow-up care, especially in the lead
up to winter when admission rates double. Professor Chris Carlin from NHS Greater Glasgow and Clyde, who presented the DYNAMIC-AI findings at the ERS Conference, said: “Our breaking new DYNAMIC-AI results show that investing in AI in healthcare could offer remarkable benefits to both patients and the NHS. We have shown that predictive AI can be used safely and effectively in patient care, this could really make a difference in allowing us to make earlier and more targeted interventions.” Funding for the study was awarded to Lenus Health through the Artificial Intelligence in Health and Care Award, one of the NHS AI Lab programmes led by NHS England. Lenus Health has achieved significant milestones in completing the DYNAMIC- AI study objectives with 130 patients recruited. The study validates the company’s existing suite of Lenus Stratify models, including mortality and admission risk prediction, and paves the way for broader applications of AI in healthcare. The technology has also been selected to pilot the MHRA’s new Innovative Devices Access Pathway (IDAP) programme, which aims to accelerate patient access to innovative medical devices.
Free student membership scheme launched by AfPP
The Association for Perioperative Practice (AfPP) has announced that, from 1st September 2024, perioperative students will be given free membership, and all existing student members will benefit too. “We’re delighted to announce the launch of a new
Free Student Membership Scheme for students on a full-time pre-registration undergraduate course,” said Alex Duke, CEO of AfPP. “We’re also introducing a Newly Qualified Member (NQM) rate of £72 for the first year after graduating, which comes with all the benefits of full registered membership. This heavily discounted rate gives additional support to newly- qualified practitioners at the start of their careers.” Ruth Collins, AfPP President, said: “This is a fabulous offer for students to become part of AfPP, while studying, and be supported to become the best perioperative practitioner they can be, with all the member benefits available to them.” AfPP’s focus is to help perioperative practitioners
develop skills and keep knowledge up to date. It is committed to improving patient care and safety through developing and promoting the leading standards for perioperative practice. “AfPP is celebrating its 60th anniversary this year,
10
www.clinicalservicesjournal.com I October 2024
Sponsored by
MicrosensDx collaborates with Imperial researchers to develop groundbreaking sepsis test
MicrosensDx has announced that it is working with The Mayr Group at Imperial College London to develop a novel biomarker test for the early recognition of sepsis. Based on MicrosensDx’s IP and technology, and designed to fit with existing diagnostic processes, this test could potentially fill a critical gap in patient management, offering clinicians a specific, quantitative diagnostic and prognostic solution to help prioritise appropriate treatment of sepsis. Sepsis affects 49 million people globally and
results in 13 million deaths
annually.There is a clear need for routine testing to enable more specific detection and prioritisation of sepsis treatment, as current biomarkers focus mainly on detecting inflammation, and most proposed biomarkers have limitations. A successful test to profile the risk of sepsis could therefore improve treatment, enable more timely and appropriate interventions, and reduce costs. MicrosensDx and Imperial are applying their joint expertise and experience in infectious diseases to address this challenge, with the aim of developing a groundbreaking sepsis test based on the detection of P Complex, which increases during serious infection, with high levels linked to poor patient outcomes. The team is working on an early-stage project to evaluate the efficacy of specific antibodies against P Complex, as part of a programme to establish the first all-in-one test to stratify the risk of patients developing severe sepsis and septic shock. “We hope that this project will establish an
innovative predictive test for sepsis, enabling earlier and more precise treatment decisions to be made,” commented Simon Walker, CEO of MicrosensDx. “The sepsis biomarkers currently in clinical
and we want to support as many students as we can through the new Free Student Membership Scheme,” said Ruth, adding: “Membership of AfPP is open to everyone working in or around the perioperative environment across the NHS and independent sector. It provides you with the tools you need to be the best practitioner you can be, and you are guaranteed to find everything you need to be a patient safety advocate and advance in your role.” To find out more about the new AfPP Free
Student Membership Scheme, and sign up, go to:
www.afpp.org.uk/membership/students/
use lack specificity, highlighting the need for new markers with the ability to effectively stratify individual patients according to their severity of risk in a dynamic and timely fashion. Together with MicrosensDx, we aim to provide proof-of-concept for a new test, which could later be evaluated to determine its ability to accurately assess patient risk and guide targeted treatment strategies,” added Professor Manuel Mayr, British Heart Foundation and Co-director of the BHF Centre of Research Excellence at Imperial.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
